We searched the databases MEDLINE and PREMEDLINE from January, 1999, to July, 2004. The keywords “colorectal cancer”, “rectal cancer”, and “colon cancer” were combined with the Boolean operator “and” with the following keywords: “epidemiology”, “risk factors”, “prevention”, “screening”, “pathogenesis”, “prognostic factors”, “diagnosis”, “treatment” (“surgery”, “radiotherapy”, “chemotherapy”), and “follow-up”. We screened the bibliography of each relevant article for further relevant
SeminarColorectal cancer
Section snippets
Epidemiology
Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer deaths worldwide. The WHO estimates that 945 000 new cases occur yearly, with 492 000 deaths.1 This cancer is more common in developed than developing countries. In developed countries, it is the second most common tumour, with a lifetime incidence of 5%, but its incidence and mortality are now decreasing.1, 2, 3 The worldwide variability of outcome is proportional to access to specialists and
Sporadic
Most cases of colorectal cancer are sporadic, and genetic and environmental factors are important (panel 1).1 About 20% of all patients with this cancer are estimated to have some component of familial risk without fulfilling the strict criteria for hereditary colorectal cancer.4 Family history should therefore always be taken when assessing a patient; the Bethesda guidelines are valuable in this context. However, taking a family history by interview often underestimates family history of
Screening and prevention
Screening is effective in reducing mortality from colorectal cancer. Screening procedures include faecal occult-blood tests, flexible sigmoidoscopy, double-contrast barium enema, and colonoscopy.18 One of these options should be offered to asymptomatic people aged 50 years or older.19 The ideal screening method is still controversial, with no test unequivocally better than another. Risk, costs, and effectiveness need to be taken into account when discussing the different options.19 Total
Pathogenesis
The adenoma-carcinoma sequence is the basis for development of colorectal cancer with corresponding accumulation of genetic changes.32, 33 Traditionally, colorectal carcinogenesis is explained by two pathways, the gatekeeper and the caretaker pathway.34 The gatekeeper pathway is responsible for about 85% of sporadic colorectal cancers, and is the mechanism of carcinogenesis in patients with FAP. Gatekeepers are genes that regulate growth. One of the key steps of this pathway is mutation of the
Prognostic factors
Prognostic factors can be divided into three main groups: patient, treatment, and tumour related factors. We mainly discuss the last two.
Diagnosis
Colonoscopy is the gold standard for diagnosis of colorectal cancer; in addition to physical examination, abdominal ultrasound and chest radiography are routinely done. The necessity of routine preoperative CT scans is still debated because this method alters the surgical approach in only a few cases.83
Better imaging of rectal cancer is important for planning of treatment. Local staging can be done by endorectal ultrasound (figure 2), CT (figure 3), or MRI (figure 4).84 High-resolution MRI is a
Treatment
Surgery is the basis of therapy for colorectal cancer, and important developments have occurred.
Radiotherapy and radiochemotherapy
Radiotherapy aims to reduce local recurrence and improve survival for patients with rectal cancer. Traditionally, adjuvant radiochemotherapy was considered standard care for patients with stage II and III rectal cancer. Neoadjuvant radiochemotherapy was reserved for advanced rectal cancers (uT4). Recently, neoadjuvant methods have been advocated for stage II and III patients too on the basis of two theoretical advantages—better local tumour control and lower morbidity.118
The Dutch CKVO 95-04
Adjuvant treatment
The use of adjuvant fluorouracil-based chemotherapy in patients with stage III colon cancer is thought to be standard care, but is not routinely recommended in stage II colon cancer.129, 130 For specific high-risk stage II patients (eg, T4-tumours, inadequate number of removed lymph nodes, perforation, bowel obstruction, poor differentiation), however, chemotherapy should be considered. Gill and colleagues62 developed a model to estimate survival benefit by adjuvant chemotherapy stratified by
Palliative chemotherapy
Palliative chemotherapy for patients with metastatic colorectal cancer aims to improve survival and quality of life. It is crucial that resectability of the metastases is assessed by experienced surgeons before and during chemotherapy to avoid missing the opportunity for potentially curative resection, since resection of metastatic disease (hepatic or pulmonary metastases) can lead to 5-year survival rates of 35–58%.137 In this context, it is important to realise that about 15% of patients with
Response prediction
Prediction of the response to chemotherapy would allow its selective use. For fluorouracil-based chemotherapy, intratumoral thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase as well as microsatellite-instability status could be such markers.154, 155, 156 For oxaliplatin, intratumoral concentrations of ERCC1 (excision repair cross-complementing), and for irinotecan, intratumoral concentrations of topoisomerase 1 seem to allow response prediction.157 However,
Follow-up
The objectives of follow-up after curative resection of colorectal cancers are improvement of survival, psychological support, quality control of medical care, and facilitation of research.158 Meta-analyses showed a significant improvement in survival after intense compared with routine follow-up (relative risk ratio 0·67–0·81).159, 160, 161 The cost for one saved year of life by follow-up is estimated at about US$6000–14000, which is judged to be acceptable.162
Because of the heterogeneity of
Future developments
The molecular genesis of colorectal cancer and therapies focusing on specific molecular targets attract the most attention and promise major advances. Individualised treatment according to genetic tumour profiles might become possible. However, we should not forget that better screening and prevention programmes could save many lives; public education should therefore be a top priority. In the future, prediction of the individual risk of colorectal cancer with individualised screening and
Search strategy and selection criteria
References (163)
- et al.
Digestive and liver diseases statistics, 2004
Gastroenterology
(2004) - et al.
High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis
Gastroenterology
(2004) Genetic testing for high-risk colon cancer patients
Gastroenterology
(2003)- et al.
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC
Gastroenterology
(1999) - et al.
Diagnosis and management of dysplasia in patients with inflammatory bowel disease
Gastroenterology
(2004) - et al.
Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence
Gastroenterology
(2003) - et al.
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis
Gastroenterology
(2003) - et al.
Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo
Gastroenterology
(2004) - et al.
Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition
Gastroenterology
(2004) - et al.
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Lancet
(2004)
Colorectal Cancer Chemoprevention: an overview of the science
Gastroenterology
The genetic pathogenesis of colorectal cancer
Hematol Oncol Clin N Am
Emerging concepts in colorectal neoplasia
Gastroenterology
Hospital volume and surgical outcomes for elderly patients with colorectal cancer in the United States
J Surg Res
The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer
Surgery
Effect of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis
J Am Coll Surg
Colorectal carcinoma: diagnostic, prognostic, and molecular features
Mod Pathol
Molecular prognosis in colorectal cancer
Surg Oncol
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Ann Oncol
Local radiological staging of rectal cancer
Clin Radiol
Anaesthesia, surgery, and challenges in postoperative recovery
Lancet
Colorectal Cancer
Cancer statistics, 2004
CA Cancer J Clin
Hereditary colorectal cancer
N Engl J Med
Accuracy of reporting of family history of colorectal cancer
Gut
Clinical management of hereditary colorectal cancer syndromes
Curr Opin Gastroenterol
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH
N Engl J Med
Duodenal adenomatosis in familial adenomatous polyposis
Gut
Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy
Ann Surg
Familial adenomatous polyposis patients without an identified APC germline mutation have a severe phenotype
Gut
Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer
Gastroenterology
Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
J Natl Cancer Inst
Colorectal cancer in inflammatory bowel disease
Curr Opin Gastoenterol
Current and future trends in colorectal cancer screening
Cancer Met Rev
Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control
J Natl Cancer Inst
Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy
Gut
Endoscopic mucosal resection: an evolving therapeutic strategy for non-polypoid colorectal neoplasia
Gut
Serum proteomics in cancer diagnosis and management
Ann Rev Med
Modifiable risk factors for cancer
Br J Cancer
Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review
Dis Colon Rectum
Pre-emptive surgery and increasing demands for technical perfection
Br J Surg
Epigenetic changes in colorectal cancer
Cancer Met Rev
Gatekeepers and caretakers
Nature
The genetics of colorectal cancer
Ann Intern Med
Genomic instability and colon cancer
Cancer Met Rev
Flat and depressed colorectal neoplasms
Curr Opin Gastroenterol
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
Am J Physiol Gastrointest Liver Physiol
Role of cylooxygenase-2 in the angiogenesis of colorectal cancer
Int J Colorectal Dis
Role of cyclooxygenase-2 in colorectal cancer
Cancer Met Rev
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis
Nat Med
Cited by (1110)
LncRNAs in necroptosis: Deciphering their role in cancer pathogenesis and therapy
2024, Pathology Research and PracticeGPC2 as a diagnostic and prognostic marker regulated progression of colorectal cancer
2024, Arab Journal of GastroenterologyFrom inflammation to metastasis: The central role of miR-155 in modulating NF-κB in cancer
2024, Pathology Research and PracticeLow expression of ZHX3 is associated with progression and poor prognosis in colorectal cancer
2024, Translational Oncology